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Recurrent  disease  occurs  in  12–37%  of patients  with vulvar  squamous  cell  carcinoma  (VSCC).  Decisions
about  treatment  of  recurrent  VSCC  mainly  depend  on  the  location  of  the  recurrence  and  previous  treat-
ment,  resulting  in  individualized  and  consensus-based  approaches.  Most  recurrences  (40–80%)  occur
within 2 years  after  initial  treatment.  Currently,  wide  local excision  is  the treatment  of choice  for  local
recurrences.  Isolated  local  recurrence  of VSCC  has  a  good  prognosis,  with  reported  5-year  survival  rates
of up  to 60%.  Groin  recurrences  and  distant  recurrences  are  less  common  and  have  an  extremely  poorquamous cell carcinoma
ecurrence
isk factors
reatment
prognosis.  For  groin  recurrences,  surgery  with  or without  (chemo)  radiotherapy  is a treatment  option,
depending  on prior  treatment.  For  distant  recurrences,  there  are  only  palliative  treatment  options.  In  this
review, we  give  an  overview  of  the  available  literature  and  discuss  epidemiology,  risk  factors,  and  prog-
nostic  factors  for the different  types  of  recurrent  VSCC  and  we describe  treatment  options  and  clinical
outcome.
© 2016  The  Author(s).  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC  BY
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1. IntroductionVulvar cancers account for 3–5% of all gynecological malignan-
cies, with an annual incidence of 1–2 per 100,000 women  (Gadducci
s article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
2 L.S. Nooij et al. / Critical Reviews in Onco
Table 1
FIGO staging system of vulvar cancer.
Stage
I Tumours conﬁned to the vulva or perineum, no nodal
metastasis Ia: Tumour ≤2 cm with stromal invasion ≤1 mm Ib:
Tumour >2 cm or stromal invasion >1 mm
II  Tumour of any size with extension to adjacent perineal
structures (lower urethra, lower vagina, anus), no nodal
metastasis
III  Tumour of any size with or without extension to adjacent
perineal structures (lower urethra, lower vagina, anus), with
inguino-femoral nodal metastasis IIIa: 1 node metastasis
(≥5 mm)  or 1–2 node metastasis(es) (<5 mm)  IIIb: ≥2 node
metastases (≥5 mm)  or ≥3 node metastases (<5 mm)  IIIc: node
metastases with extra-capsular spread
IV Iva: Tumour invades any of the following: upper urethra
and/or vaginal mucosa, bladder mucosa, rectal mucosa, or
e
B
w
e
d
b
t
8
m
b
s
e
(
d
a
S
n
s
n
l
B
l
b
a
(
p
u
2
C
1
o
i
b
p
k
a
T
O
I
sﬁxed to pelvic bone, or ﬁxed or ulcerated inguinofemoral
nodes IVb: Any distant metastasis including pelvic nodes
t al., 2006; Hacker et al., 2012; de Hullu and van der Zee, 2006;
erek and Hacker, 2014). The incidence of vulvar cancer increases
ith age, with a peak incidence in the seventh decade (Gadducci
t al., 2006; de Hullu and van der Zee, 2006). The overall inci-
ence of vulvar cancer has risen over the last decade, probably
ecause of an increase in human papilloma virus (HPV) infec-
ions and higher life expectancy (Schuurman et al., 2013). Around
0–90% of these tumors are squamous cell carcinomas. Malignant
elanoma, Bartholin gland carcinoma, invasive Paget’s disease, and
asal cell carcinoma are less frequent. Other tumor types, such as
arcomas and verrucous carcinomas, are extremely rare (Gadducci
t al., 2006; Hacker et al., 2012; de Hullu and van der Zee, 2006).
Five year survival for early-stage VSCC is about 80–90%
Gadducci et al., 2006; Gonzalez et al., 2005). Prognosis is strongly
ependent on the presence of lymph node metastases (de Hullu
nd van der Zee, 2006; Gonzalez et al., 2005; Gadducci et al., 2012;
alom and Penalver, 2002; Rouzier et al., 2002). Therefore, the Inter-
ational Federation of Gynecology and Obstetrics (FIGO) staging
ystem was changed in 2009 (Table 1) (FIGO, 2014). Tumors with
egative lymph node status can be regarded as low risk, regard-
ess of tumor diameter and expansion to the vagina and/or urethra.
y contrast, the number, size, and extranodal growth of involved
ymph nodes are important prognostic factors. An increasing num-
er of positive lymph nodes, a larger diameter of nodal metastases,
nd extranodal growth are signiﬁcantly related to worse survival
van der Steen et al., 2010).
Carcinogenesis of VSCC can be subdivided into two different
athways. One pathway is associated with lichen sclerosus (LS) and
sually occurs in older patients (55–85 years) (Berek and Hacker,
014; Al-Ghamdi et al., 2002; Alonso et al., 2011; Canavan and
ohen, 2002; Kokka et al., 2011; Lindell et al., 2010; Monk et al.,
995; Bloss et al., 1991). This pathway accounts for around 70%
f all VSCC. Differentiated vulvar intraepithelial neoplasia (dVIN)
s the presumed precursor lesion found in this type of VSCC. It has
een suggested that untreated dVIN has a high malignant potential,
robably as high as 80% (van de Nieuwenhof et al., 2008). The other
nown pathway is human papilloma virus (HPV) dependent and
ccounts for around 30% of all VSCC. The most prevalent HPV types
able 2
ld and new terminology of vulvar squamous intraepithelial lesions.
ISSVD 1986 ISSVD 2004 
VIN 1 Flat condyloma or HPV effect 
VIN  2 VIN 3 VIN, usual type (uVIN) 
Differentiated VIN (dVIN) VIN, differentiated type (dVIN) 
SSVD International Society for the Study of Vulvovaginal Disease; VIN Vulvar Intraepith
quamous intraepithelial lesion.logy/Hematology 106 (2016) 1–13
found in VSCC are HPV16 in 60–78% of cases followed by HPV18
in 5–16% (Alonso et al., 2011; Canavan and Cohen, 2002; Lindell
et al., 2010; Monk et al., 1995; Bloss et al., 1991; Ansink et al., 1994;
Coleman and Santoso, 2000; Larsson et al., 2012; Pinto et al., 2004;
Hording et al., 1993; van de Nieuwenhof et al., 2009). This pathway
usually occurs in younger patients (35–65 years) and is associated
with vulvar high grade squamous intraepithelial lesions (HSIL, for-
merly referred to as usual type VIN) and smoking. Untreated vulvar
HSIL has a lower rate of progression to VSCC (9–16%) (Kokka et al.,
2011; van de Nieuwenhof et al., 2008) compared to dVIN. Although
most VSCC are HPV independent, dVIN accounts for only 2–10% of
all reported VIN lesions (Kokka et al., 2011; van de Nieuwenhof
et al., 2009). The low prevalence of dVIN may  be explained by the
belief that it progresses rapidly to VSCC. Another explanation may
be that dVIN is an underdiagnosed and therefore underreported
lesion due to its subtle clinical and histological features. Although
dVIN has been described already in 1961 by Abell et al. (Abell and
Gosling, 1961), it is only recently that dVIN has been recognized and
regarded as a distinctive diagnosis by clinicians as well as pathol-
ogists (Kokka et al., 2011). Recently, the International Society for
the Study of Vulvar Disease (ISSVD) published a new classiﬁcation
system for VIN. The new terminology discriminates between HPV-
dependent low-grade squamous intraepithelial lesions (LSIL; i.e.,
ﬂat condyloma or HPV effect) and high-grade squamous intraep-
ithelial lesions (HSIL) on the one hand, and the HPV-independent
precursor dVIN on the other (Table 2) (Bornstein, 2015). Because
precursor lesions are frequently found in the presence of VSCC,
clinicians should take the phenomenon of “ﬁeld cancerization” into
account: the majority of “recurrences” maybe considered “de novo”
tumors in a background of epithelial changes already at risk for
the development of malignancy (van de Nieuwenhof et al., 2008;
Torezan and Festa-Neto, 2013; Braakhuis et al., 2003).
Surgery is the cornerstone of treatment for primary VSCC
(Gadducci et al., 2006; Hacker et al., 2012; Berek and Hacker,
2014). Surgery for tumors inﬁltrating >1 mm generally consists of
wide local excision with full uni- or bilateral inguinofemoral lym-
phadenectomy (IFL) or sentinel lymph node (SLN) biopsy. A full IFL
is deﬁned as the surgical removal of all lymph node–bearing fatty
tissue of the superﬁcial inguinal and deep femoral loge medial to
the fossa ovalis. SLN biopsy is considered safe in a selected group
of patients with VSCC: those with a unifocal vulvar tumor < 4 cm
without enlarged or clinically suspected groin lymph nodes upon
palpation and imaging (van der Zee et al., 2008). Adjuvant radi-
ation therapy is indicated for close or involved surgical margins
and lymph node involvement depending on the size and number of
nodal metastases and the presence of extranodal growth. Concur-
rent chemoradiotherapy in a neoadjuvant setting is recommended,
especially for downsizing of bulky disease, in particular when the
urethra or anus are involved (Hacker et al., 2012; de Hullu and van
der Zee, 2006; van der Zee et al., 2008; Oonk et al., 2010a; Oonk
et al., 2010b; van den Einden et al., 2012). Despite these treat-
ment modalities, recurrence rates are still high: 12–37% (Gadducci
et al., 2012; Coulter and Gleeson, 2003). Furthermore, prognosis
of patients with recurrent VSCC has not improved over the past
decades, with a reported 5-year survival rate of 25–50% (Coulter
ISSVD 2015
LSIL
HSIL
VIN, differentiated type (dVIN)
elial Neoplasia; LSIL Low grade squamous intraepithelial lesion; HSIL High grade
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nd Gleeson, 2003; Cormio et al., 2010; Hopkins et al., 1990; Oonk
t al., 2006; Stehman et al., 1996).
There are several challenges in the treatment of recurrent VSCC.
ost VSCC patients are over 60 years of age, with signiﬁcant comor-
idity. Moreover, treatment of recurrent VSCC is associated with
 high risk of developing complications (Schuurman et al., 2013;
an de Nieuwenhof et al., 2009). The choice of treatment for recur-
ent VSCC is determined by the localization of recurrence and prior
reatment (Salom and Penalver, 2002; Coulter and Gleeson, 2003;
eikel et al., 2006). Nevertheless, the literature is relatively scarce
nd clear guidelines for the treatment of recurrent VSCC are lacking
Guideline vulvar cancer, national cancer institute, 2015; Guideline
ulvar cancer, oncoline, 2011; Guidelines for the Diagnosis and
anagement of Vulval Carcinoma, RCOG, 2014). In this review,
e present an overview of the available literature on known risk
actors for recurrence and treatment options for recurrent VSCC,
ncluding associated morbidity and clinical outcome.
.1. Data sources
We  performed an extensive search on PubMed, Embase, Web
f Science, Cochrane, and ScienceDirect. After consulting a medical
ibrarian, we  formulated a combination of Medical Subject Head-
ngs (MeSH) and free text words. Our search included the terms
ulvar neoplasm, vulvar carcinoma, vulvar neoplasia, groin, metas-
asis, and recurrence. The electronic search was complemented
y a manual search of reference lists for relevant publications. In
ddition, we collected information from national and international
ncological guidelines and checked study books for further data
Berek and Hacker, 2014; Guideline vulvar cancer, national cancer
nstitute, 2015; Guidelines for the Diagnosis and Management of
ulval Carcinoma, RCOG, 2014; Hacker et al., 2010; Ayhan et al.,
010; Guideline vulvar cancer, oncoline, 2011).
A total of 1303 articles were identiﬁed. All articles were assessed
y two independent authors (LN and FB) on title, abstract, or full
rticle. Inclusion criteria were original articles that reported on
reatment of recurrent VSCC (either local, groin or distant recur-
ences). To avoid inclusion of too small studies we  chose to only
eport studies that included a minimum of respectively 20 or 10
atients (local or groin recurrence). After exclusion of articles based
pon title and abstract 67 articles remained of which the full article
as judged. Finally, twenty-four articles met  our inclusion criteria
nd were included in this review.
.2. Terminology
There is no clear deﬁnition of local VSCC recurrence in the cur-
ent literature. There is no consensus on the minimum or maximum
ime span until local recurrence and on the distance between recur-
ent disease and the initial or primary vulvar tumor. Some authors
eﬁne local recurrence as the new appearance of a tumor after
herapy with radical intent and a disease-free period of at least
 months (Maggino et al., 2000). Rouzier et al. deﬁned three pat-
erns of local recurrence: primary tumor site recurrence, remote
ulvar recurrence (>2 cm from the primary tumor site), and skin
ridge recurrence (Rouzier et al., 2002). Because documentation of
he exact location of the primary tumor is often equivocal, the dis-
ance to the primary site to deﬁne recurrence is difﬁcult to assess.
n ongoing and future prospective studies, introduction of digital
ameras may  be helpful in reporting the exact location of the tumor.
nother point of discussion addresses the time span that should be
sed to deﬁne tumor recurrence versus de novo tumor. Most recur-
ences occur within 2 years after primary treatment, so recurrences
fter 2–3 years might be considered de novo tumors (Coulter and
leeson, 2003; de Hullu et al., 2002).logy/Hematology 106 (2016) 1–13 3
For this review, we deﬁned a local recurrence as a “new or de
novo” tumor on the vulva after primary treatment of VSCC, irre-
spective of location on the vulva, distance from the primary tumor,
or time interval from initial therapy to recurrence. We  stand by this
deﬁnition because differences in these features were not described
clearly in the available literature. A groin recurrence is deﬁned
as any (recurrent) lymph node metastasis in the groin(s) with or
without the presence of a local recurrence after initial treatment
for VSCC. A skin bridge recurrence is considered a special type of
locoregional recurrence and is deﬁned as a new tumor in the der-
mis  in the intervening skin between the operated-on vulva and the
ipsilateral groin region. Distant or metastatic recurrence is deﬁned
as any recurrence beyond the vulva or groins, whether or not asyn-
chronous with a local or groin recurrence. Pelvic recurrences are
considered distant recurrences.
2. Epidemiology and risk factors
Recurrences of VSCC occur in 12–37% of patients after initial
treatment, depending on tumor stage at initial diagnosis (Gadducci
et al., 2012; Coulter and Gleeson, 2003); 40–80% of all recur-
rences occur within 2 years of initial treatment (Gadducci et al.,
2006; Coulter and Gleeson, 2003). Outcome for patients who had
recurrences within 2 years after initial surgery is worse compared
to patients who  had recurrences >2 years after initial treatment
(Salom and Penalver, 2002; Piura et al., 1993). In a prospective study
of 143 patients with VSCC, Stehman et al. found a median time
until local recurrence of 35.9 months: 19% of the VSCC recurred
in the ﬁrst year after therapy, and 28.6% recurred in the ﬁrst 2
years after therapy. All patients included in this study underwent
surgery to remove the local tumor, consisting of a modiﬁed radical
hemivulvectomy or radical vulvectomy. Primary groin treatment
consisted of superﬁcial inguinal lymphadenectomy in 120 patients
and groin irradiation in 23 patients (Stehman et al., 1996). Another
study identiﬁed local recurrences in the ﬁrst year after treatment
in 39% of patients, with an equal distribution during the following
years (Maggino et al., 2000). A recently published study reporting
long term follow-up data of the GROINSS-VI study in patients with
unifocal VSCC found a local recurrence rate of 27% after 5 years,
with a median time to local recurrence of 33 months (range 2–128
months). The reported local recurrence rate at 10 years was as high
as 40%. This ‘recurrence’ rate after 10 years was even higher than
expected later in the course of disease (Te Grootenhuis et al., 2016).
Mean follow-up after initial treatment was  shorter in most previous
studies compared to the long-term follow-up of the GROINSS-VI
study. This might have underestimated the true incidence of recur-
rent disease. Furthermore, it still can be argued whether recurrent
disease after several years must be regarded as true recurrence
or de novo disease. Because of late “recurrences”, several guide-
lines advise lifelong follow-up after treatment for VSCC (Guideline
vulvar cancer, oncoline, 2011; Guidelines for the Diagnosis and
Management of Vulval Carcinoma, RCOG, 2014). Routinely sched-
uled follow-up leads to detection of smaller local recurrences in a
considerable proportion of patients (Oonk et al., 2003). The median
time until recurrence in the groin is 7 months. The majority of the
groin recurrences (67–73%) occur in the ﬁrst year after initial treat-
ment (Stehman et al., 1996; Maggino et al., 2000; Te Grootenhuis
et al., 2016). Distant recurrences predominantly occur within 2
years after initial treatment (Maggino et al., 2000; Te Grootenhuis
et al., 2016).2.1. Local recurrence
The incidence of isolated local recurrences is 20–23% (Maggino
et al., 2000; Te Grootenhuis et al., 2016; Woolderink et al., 2006).
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Table 3
Prevalence of HPV in VSCC and inﬂuence of HPV presence on prognosis.
Author No of patients No HPV positive No HPV negative Clinical outcome HPV
positive
Clinical outcome HPV
negative
Clinical outcome
p-value
(Larsson et al., 2012) 130 31% 69% RR 30% OS 67% RR 44% OS 43% RR p = 0.121 OS
p = 0.029
(Alonso et al., 2011) 98 19% 81% RR 60% OS 67% RR 50% OS 71% RR p = 0.885. Number
of local recurrences
lower in HPV  positive
VSCC (16% vs 37%,
p = 0.049) OS p = 0.789
(Lindell et al., 2010) 75 31% 69% RR NS OS 100% RR NS OS 65% RR HPV positive better
disease free survival;
p = 0.004 OS  p = 0.001
(van de Nieuwenhof
et al., 2008)
130 35% 65% RR NS OS NS RR NS OS NS RR NS OS p = 0.646
(Pinto et al., 2004) 161 24% 76% RR 50% OS 63% RR 35% OS 71% RR p = 0.055 OS
p = 0.447
*(Rouzier et al., 2001) 77 32% vulvar HSIL
adjacent to the VSCC
68% LS or dVIN
adjacent to the VSCC
RR 10% OS 87% RR 35% OS 42% RR p < 0.05 OS p < 0.01
(Monk et al., 1995) 55 60% 40% RR 27% OS 72% RR 55% OS 44% RR p = 0.041 OS p = 0.01
(Ansink et al., 1994) 60 32% 68% RR NS OS NS RR NS OS NS RR NS OS HPV positive
better OS; p = 0.003
(Hording et al., 1993) 62 31% 69% RR NS OS NS RR NS OS NS RR not signiﬁcant OS
NS
(Bloss et al., 1991) 21 48% 52% RR 20% OS 90% RR 45% OS 82% RR not signiﬁcant OS
not signiﬁcant
*
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PV: human papilloma virus; VSCC: vulvar squamous cell carcinoma; RR: recurren
ore than 50% of all recurrences are local (Gadducci et al., 2012;
alom and Penalver, 2002; Coulter and Gleeson, 2003; Stehman
t al., 1996; Maggino et al., 2000; Woelber et al., 2009); they are
ainly isolated or associated with the groin or distant recurrences
Gadducci et al., 2012; Stehman et al., 1996; Maggino et al., 2000;
oelber et al., 2009). Univariate risk factors for local recurrence are
igher age (Woolderink et al., 2006; Woelber et al., 2009), greater
umor size (Coulter and Gleeson, 2003; Woelber et al., 2009; Preti
t al., 2000; Rutledge et al., 1991), a multifocal tumor (Preti et al.,
000), depth of invasion >2 mm (Rouzier et al., 2002; Woelber et al.,
009; Bogani et al., 2014; Yoder et al., 2008), lymphovascular space
nvasion (Preti et al., 2000), and the presence of lymph node metas-
ases at initial treatment (Gonzalez et al., 2005; Maggino et al.,
000; Woelber et al., 2009). Except for greater tumor size, all of
hese risk factors are independent risk factors for local recurrence
n multivariate analyses. A recent study identiﬁed the presence
f perineural invasion as an independent pathological risk factor
or local recurrence (Holthoff et al., 2015). The presence of lymph
ode metastases at initial treatment may  reﬂect a more aggres-
ive biological behavior of the tumor and therefore also a poor
rognostic factor for local recurrence. Few studies have reported
n the presence of precursor lesions as risk factors for local recur-
ence. Two studies found that LS is a risk factor for recurrent disease
Woolderink et al., 2006; Regauer, 2011). One study compared the
resence of associated HSIL as a prognostic factor for recurrence
ith the absence of associated HSIL (relative risk 2.30, p < 0.019)
Preti et al., 2000). Another study found that the presence of HSIL
n the surgical margins resulted in a 3-fold higher risk of recur-
ence (p = 0.03) (Modesitt et al., 1998). The width of the tumor-free
argin status is one of the most clinical important and controver-
ial topics in vulvar cancer treatment. Although it is obvious that a
umour positive margin is associated with an increased local recur-
ence rate, the association of the width of the tumor-free margin
nd local recurrence rate is less clear (de Hullu et al., 2002; Heaps
t al., 1990; Viswanathan et al., 2013; Groenen et al., 2010; Chan
t al., 2007; Woelber et al., 2011). Heaps et al. (Heaps et al., 1990)
ound that increasing tumor-free margins were associated with a
ecrease in the local recurrence rate in a group of 135 patients. In
atients with a tumor-free margin of <8 mm,  there was  a 48% risk of; OS: overall survival; NS: not speciﬁed.
local recurrence, compared to a 0% local recurrence rate for patients
with a tumor-free margin of >8 mm (Heaps et al., 1990). How-
ever, subsequent studies yielded varying results with regard to the
tumor-free margin and the risk of local recurrence (de Hullu et al.,
2002; Viswanathan et al., 2013; Groenen et al., 2010; Chan et al.,
2007; Woelber et al., 2011). Moreover, in most of these studies, the
difference between “true recurrences” and “de novo” tumors was
not taken into account. Future studies should focus on investigating
the optimal tumor-free margin for prevention of local recurrences.
2.2. Groin recurrence
In 9–38% (average 22%) of patients with recurrent VSCC, the
groin is the site of recurrence (Gonzalez et al., 2005; Coulter and
Gleeson, 2003; Stehman et al., 1996; Woolderink et al., 2006;
Woelber et al., 2009; Deka et al., 2014; Woelber et al., 2012; Lataifeh
et al., 2004). Patients with lymph node involvement at initial diag-
nosis have a higher risk of developing a groin recurrence (Gonzalez
et al., 2005; Stehman et al., 1996; Woolderink et al., 2006; Woelber
et al., 2009; Deka et al., 2014; Lataifeh et al., 2004). In patients
with negative lymph nodes at initial diagnosis, the groin recurrence
rate is estimated to be extremely low (0–2%), while for patients
with positive lymph nodes, this risk is as high as 29–40% (van der
Zee et al., 2008; Woelber et al., 2009; Deka et al., 2014; Woelber
et al., 2012). SLN procedure of the groin is the preferred staging
in patients with unifocal disease <4 cm without enlarged or clini-
cally suspected lymph nodes (van der Zee et al., 2008). In all other
primary cases and local recurrences without earlier IFL a full IFL
should be performed. The risk of groin recurrence can be reduced
considerably with adjuvant radiotherapy to the inguinofemoral and
pelvic region (de Hullu and van der Zee, 2006; Mahner et al., 2015;
Homesley et al., 1986; Kunos et al., 2009). Because radiotherapy was
not always applied routinely in case of positive nodes, in particular
in older studies, the groin recurrence risk could be overestimated
compared to today’s standard treatment. Adjuvant radiotherapy
is recommended in patients with lymph node involvement when
there are two or more positive lymph nodes or in case of extracap-
sular extension (de Hullu and van der Zee, 2006).
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Table 4
Treatment of local recurrence of VSCC.
Study Total Local Local &
groin
Beyond
vulva*
Surgery Surgery + RT RT only C-RT No
treatment/
palliative
Re-
recurrences
5- year
survival**
Note
(Weikel et al.,
2006)
N = 201 Ns ns Ns N = 201
(100%)
68% after 5
years.
45% Authors did not
specify treatment
for location of
recurrent disease
(Chakalova and
Karagiozov,
1993)
N = 102 N = 72
(70%)
N = 18
(18%)
N = 12
(12%)
N = 81
(79%)
N = 21
(21%)
NS 61% 79% of patients
with a local
recurrence were
free of disease at
last follow-up
(Kohler et al.,
1997)
N = 82 N = 39
(47%)
N = 27
(33%)
N = 16
(20%)
N = 33
(40%)
N = 16
(20%)
N = 33
(40%)
17 (35%) 46.9% Re-recurrence
occurred after 12,8
months on average.
(Piura et al.,
1993)
N = 73 N = 39
(53%)
N = 34
(47%)
N = 41
(56%)
N = 7 (10%) N = 5 (7%) N = 20
(27%)
NS 35.2% At last follow up,
73% of all patients
treated surgically
were alive versus
25% of all patients
treated with RT.
(Schmidt et al.,
1992)
N = 51 N = 28
(55%)
N = 3 (6%) N = 20
(39%)
N = 19
(37%)
N = 20
(39%)
N = 7 (14%) N = 5 (10%) 19 (37%) 61%
(Faul et al.,
1998)
N = 47 N = 47
(100%)
N = 31
(66%)
N = 6 (13%) N = 6 (13%) N = 2 (4%) N = 2 (4%) 13 (28%)
local, 6
(13%) groin
or distant
40% Mean time to
re-recurrence 1,1
yr.
(Frischbier and
Wenn, 1985)
N = 41 N = 41
(100%)
N = 41
(100%)
NS 19.5% All patients
received
radiotherapy as
treatment for their
primary tumor.
(Strauss and
Lampe, 1994)
N = 37 N = 28
(76%)
N = 4 (11%) N = 5 (13%) N = 18
(49%)
N = 8 (22%) N = 7 (19%) 50% 56% For 4 patients
treatment was  NS
Study  Total Local Local &
groin
Beyond
vulva*
Surgery Surgery + RT RT only C-RT No
treatment/
palliative
Re-
recurrences
5- year
survival**
Note
(Hopkins et al.,
1990)
N = 34 N = 24
(71%)
N = 6 (17%) N = 4 (12%) N = 27
(79%)
N = 7 (21%) 15 (44%) 61%
(Simonsen,
1984)
N = 32 N = 29
(91%)
N = 3 (9%) N = 25
(78%)
N = 5 (16%) N = 1 (3%) N = 1 (3%) NS NS 34% had no
evidence of disease
at last follow up.
(Buchler et al.,
1979)
N = 21 N = 18
(86%)
N = 3 (14%) N = 13
(62%)
N = 1 (5%) N = 7 (33%) 5 (38%)
after S, 2
(29%) after
RT
NS Survival 43 months
after S and 26
months after RT.
(Raffetto et al.,
2003)
N = 20 N = 6 (30%) N = 6 (30%) N = 8 (40%) N = 9 (45%) N = 11
(55%)
NS 20%
Only studies that reported on a minimum of 20 patients were included:
S:  Surgery; RT: Radiotherapy; CT: Chemotherapy; C-RT: Chemoradiotherapy; NS: Not speciﬁed; CR: Complete response; PR: Partial response.
*:  Beyond vulva: all VSCC recurrences without a local component.
*For all patients: local, groin and distant recurrences.
*** Radiotherapy sometimes combined with chemotherapy: not speciﬁed.
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Table 5
Treatment of groin recurrence of VSCC.
Study Total Local &
groin
Isolated
groin
Surgery Surgery + RT RT CT Response Progression-
free
survival
Overall
survival
Note
(Frey et al.,
2016)
N = 30 N = 30* (7
patients
had groin
and pelvic
recurrence)
N = 7 (23%) N = 20
(66%), 10
patients
received
surgery
and C-RT
N = 1 (3%) N = 1 (3%) NS NS 50% 5-year
survival
Patients with
multimodal groin
treatments performed
better than tose with
single-mode treatment
(hazard ratio 0.25,
p  = 0.037) * No data
available of 1 patient
(Cormio et al.,
2010)
N = 21 N = 4 (21%),
2 local,
groin &
distant
recurrence
N = 17
(81%)
N = 3 (14%) N = 7 (34%) N = 2 (10%) N = 3 (14%) NS NS Median: 9
months
(range
3–30)
95% of the patients
died, 1 patient alive
after 60 months after
surgical treatment. 3
(14%) patients received
surgery and CT and 3
(14%) patients refused
treatment.
(Hopkins et al.,
1990)
N = 10 N = 6 (60%) N = 4 (40%) N = 4 (40%) N = 6 (60%) NS 0/10 10% 5-year
survival
(Simonsen,
1984)
N = 12 N = 3 (25%) N = 9 (75%) N = 1 (8%) N = 4 (34%) N = 7 (58%) NS NS Median: 6
months
(0.1–3.5
years). 8,3%
5-year
survival
1 patient had NED after
6  years. She was
treated with surgery
and RT.
(Tilmans et al.,
1992)
N = 12 N = 12
(100%)
N = 5 (42%) N = 5 (42%) N = 1 (8%) NS 17% Median: 10
months
2 patients received
cyclophosphamide &
cisplatin after S + RT. 1
patient received
supportive care
(Wagenaar
et al., 2001)
N = 13 N = 13
(100%)
N = 13
(100%)
PR: 54%,
7/13
Median: 4
months
(range
2–22)
Median: 9
months
(range
2–31)
CT: bleomycin,
methotrexate & CCNU.
(Witteveen
et al., 2009)
N = 11 N = 5 (45%) N = 6 (55%) N = 11
(100%)
CR + PR
27%, 3/11
Median:
2,6 months
(2–4,2
months).
10,3%
1-year pro-
gression
free-
survival
Median:
6,9 months
(range
3,5–12,4).
31% 1-year
OS
Patients were not
amenable to surgery or
radiotherapy. Response
and overall survival is
for all patients included
in the study (total 29,
all patients with locally
advanced or recurrent
VSCC) CT: paclitaxel.
Only studies that reported on a minimum of 10 patients were included:
S:  Surgery; RT: Radiotherapy; CT: Chemotherapy; C-RT: Chemoradiotherapy; CT: Chemotherapy; NS: Not speciﬁed; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; NED: no evidence of
disease.
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The number of positive lymph nodes is also a strong risk fac-
or for groin recurrences (Gadducci et al., 2012; Chan et al., 2007;
oelber et al., 2012; Hacker et al., 1983; Aragona et al., 2014).
acker et al. found that patients with more than three positive
ymph nodes had a 33% risk of groin recurrence, compared to 2.9%
or patients with less than three positive lymph nodes (Hacker
t al., 1983). Three studies described the impact of the number of
emoved lymph nodes at IFL on groin recurrence rate, with higher
isk of groin recurrences and/or poorer survival after removal of
ess than 9–12 lymph nodes (Courtney-Brooks et al., 2010; van
eekhuizen et al., 2014; Baiocchi et al., 2013). However, it should
e taken into account that removal of more lymph nodes and/or
ltrastaging will lead to the identiﬁcation of more and possibly
therwise-undetected lymph node metastases (Courtney-Brooks
t al., 2010; Chen et al., 2006). This could be a possible source of bias
n the reported results. Other prognostic clinicopathological vari-
bles for groin recurrences are advanced FIGO stage (Woolderink
t al., 2006), size of the lymph node metastases (Gadducci et al.,
012; Oonk et al., 2010b; Paladini et al., 1994), and extracapsular
odal spread (Gadducci et al., 2012; Bogani et al., 2014; Aragona
t al., 2014). In addition, groin treatment limited to superﬁcial groin
ode dissection instead of a full IFL is associated with an increase
n groin recurrences (Ansink and van der, 2000). The SLN proce-
ure has been proven safe in these patients (403 patients in the
ROINSS-V-I study), with a recurrence rate of 2.3% in patients with
 negative SLN (van der Zee et al., 2008). In addition, the risk of
roin recurrence is associated with the size of lymph node metas-
asis. Oonk et al. found lower disease-speciﬁc survival for patients
ith SLN metastases >2 mm (69.5%) compared to patients with SLN
etastases ≤2 mm (94.4%, p = 0.001) (Oonk et al., 2010b).
.3. Distant recurrence
Distant recurrences are found in approximately 8% of patients
ith recurrent disease, and most distant recurrences occur within
he ﬁrst 2 years after treatment (84%) (Gonzalez et al., 2005; Coulter
nd Gleeson, 2003; Maggino et al., 2000). The most common dis-
ant recurrence is pelvic recurrence (5–19% of the recurrences),
hich nearly always occurs together with a groin recurrence. Inci-
ence of pelvic recurrence is dependent on treatment strategy as
as shown by Homesley et al. (1986). In this study, 114 eligible
atients with VSCC and positive groin nodes after radical vulvec-
omy and bilateral lymphadenectomy were randomized to receive
ither radiation therapy or pelvic node resection. In the radiother-
py group 68% remained free of recurrence, and rates of groin and
elvic recurrence were 5.1 and 6.8%, respectively. In the pelvic
ode dissection group, 55% remained recurrence-free, while rates
f groin and pelvic recurrence were 23.6 and 1.8%. The estimated
wo-year survival rates were 68% for the radiation therapy group
nd 54% for pelvic node resection group (Homesley et al., 1986).
ultiple-site recurrences are described in about 14% of patients
ith recurrent disease (Coulter and Gleeson, 2003; Maggino et al.,
000). Advanced stage of disease is a risk factor for the develop-
ent of distant as well as multiple-site recurrences (Gadducci et al.,
012; Maggino et al., 2000; Woolderink et al., 2006; Lataifeh et al.,
004).
.4. HPV as a risk factor
In the last few years, more data have become available on the
ole of HPV in carcinogenesis. Infections with HPV have been linked
o the development of vulvar, vaginal, cervical, anal and head and
eck cancer, especially oropharyngeal malignancies (Chung and
illison, 2009; Fakhry et al., 2008; Ragin and Taioli, 2007; de Martel
t al., 2012; Mensah et al., 2016). Like squamous cell carcinoma of
he head and neck, VSCC can be subdivided into two different types:logy/Hematology 106 (2016) 1–13 7
HPV independent and HPV dependent (Alonso et al., 2011; Monk
et al., 1995; van de Nieuwenhof et al., 2008). For head and neck
carcinomas, it has become clear that these two  types are clinically
distinct with regard to response to treatment and survival outcome,
with HPV positivity as a favorable prognostic biomarker (Chung and
Gillison, 2009; Fakhry et al., 2008; Ragin and Taioli, 2007).
There are conﬂicting data about the role of HPV status as a
prognostic factor in VSCC. An overview of studies on the pres-
ence of HPV and impact on prognosis is given in Table 3 (Alonso
et al., 2011; Lindell et al., 2010; Monk et al., 1995; Bloss et al.,
1991; Ansink et al., 1994; Larsson et al., 2012; Pinto et al., 2004;
Hording et al., 1993; van de Nieuwenhof et al., 2009). The presence
of HPV DNA can be detected by PCR (sequencing or INNO-LiPA)
or in situ hybridization. HPV-independent VSCC are more com-
mon  and seem to have a higher recurrence rate (mean 44%) and
worse overall survival (mean 60%) compared to HPV-dependent
VSCC (mean 26% and 78%, respectively), although no deﬁnitive
conclusions can be drawn because of varying results and dif-
ferent deﬁnitions of HPV positivity (Lindell et al., 2010; Monk
et al., 1995; Ansink et al., 1994; Larsson et al., 2012). VSCC asso-
ciated with HSIL have a better prognosis with regard to local
recurrence, disease-free survival, and overall survival compared to
VSCC associated with LS and/or dVIN (Kokka et al., 2011; van de
Nieuwenhof et al., 2009; Rouzier et al., 2001). One  possible expla-
nation for the prognostic difference between HPV-dependent and
HPV-independent VSCC might be due to a better response to treat-
ment of HPV-dependent cancers as has been shown in head and
neck squamous cell carcinoma (Chung and Gillison, 2009; Fakhry
et al., 2008). Of the studies included in Table 3, only the study of
Alonso et al. reported on the speciﬁc treatments in HPV+ and HPV-
VSCC and found no differences between the two groups (Alonso
et al., 2011).
2.5. Prognosis
In general, 5-year survival for recurrent VSCC is reported to
be 25–50% compared to 50–90% for patients with primary VSCC
(Guideline vulvar cancer, national cancer institute, 2015; Piura
et al., 1993; Preti et al., 2000; Faul et al., 1998; Tilmans et al., 1992).
Prognosis is mainly inﬂuenced by the presence of groin metastases
at initial diagnosis. In addition, age, comorbidity, advanced FIGO
stage, and tumor characteristics are important factors for progno-
sis and outcome (Salom and Penalver, 2002; Rouzier et al., 2002;
Maggino et al., 2000; de Hullu et al., 2002; Te Grootenhuis et al.,
2016; Woolderink et al., 2006; Woelber et al., 2009; Deka et al.,
2014; Paladini et al., 1994; Faul et al., 1998; Onnis et al., 1992). More
recently, morphological factors such as spindle cell morphology
and molecular changes, especially mutations in HRAS, were shown
to be associated with poor prognosis in VSCC (Trietsch et al., 2013;
Trietsch et al., 2014; Drew et al., 1996). Furthermore, prognosis is
inﬂuenced by the site of recurrence and the time interval between
initial diagnosis and recurrent disease. Five-year survival after diag-
nosis of recurrent disease for patients with early local recurrence
(<24 months after primary treatment) was 53%, compared to 76%
for patients with late local recurrence (>24 months after primary
treatment) (p = 0.05) (Te Grootenhuis et al., 2016; Schmidt et al.,
1992). The prognosis for patients with groin and/or skin bridge
recurrence of VSCC is very poor with 5-year survival rates of only
0–10% (Coulter and Gleeson, 2003; Cormio et al., 2010; Hopkins
et al., 1990; Woolderink et al., 2006; Tilmans et al., 1992; Simonsen,
1984; Wagenaar et al., 2001; Witteveen et al., 2009; Chakalova and
Karagiozov, 1993). However, a recently published study found an
overall survival rate of 50% after 7 years for patients with a groin
recurrence (Frey et al., 2016).
8 L.S. Nooij et al. / Critical Reviews in Oncology/Hematology 106 (2016) 1–13
Table 6
Chemotherapy for patients with distant recurrent VSCC.
Study No patients distant
recurrent disease
CT regimen Response Survival Note
(Witteveen et al., 2009) 8 distant (22 total) Paclitaxel CR 7% PR 7% Overall
response 14%
Median 6.9 months
1-year survival 31%
4 patients discontinued
treatment for toxicity
(Raffetto et al., 2003) 7 distant Cisplatin or Cisplatin
with 5 FU
CR 20% (1/5) PR 80%
(4/5)
Median; 6 months
(range 2–16). Mean;
8,2 months.
All patients also got
radiotherapy. Five
patients were treated
with chemotherapy
concomitantly or
neo-adjuvant.
(Tilmans et al., 1992) 11 distant 5 FU, Cisplatin,
Aziridinyl-
benzequinone,
etoposide, doxorubicin,
cyclophosphamide
PD 100% Median; 4 months
pelvic recurrence and 5
months distant
recurrence
All treated with a
palliative intention
(Durrant et al., 1990) 10 distant Bleomycin,
methotrexate and
iomustine
6/10 (60%) showed a
partial or complete
response
ns Administered to
patients ineligible for
surgical treatment. 33%
of the patients
discontinued
treatment due to
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. Diagnosis and clinical evaluation
Symptoms of local recurrences differ, and patients may  be
symptomatic. The diagnostic workup of patients with recurrent
SCC includes a complete medical history and full gynecological
xamination. All clinically suspect vulvar areas should be biopsied
o conﬁrm diagnosis and to glean information about the extent of
isease. Fine-needle aspiration of suspected groin lymph nodes
s needed to conﬁrm the diagnosis (Hacker et al., 2012; Berek
nd Hacker, 2014; Coulter and Gleeson, 2003; Fonseca-Moutinho,
005). For assessment of regional and distant metastases, com-
uted tomography (CT) scans of the pelvis, abdomen, and chest
re recommended (Hacker et al., 2012; Berek and Hacker, 2014;
onseca-Moutinho, 2005). A positron emission tomography–CT
can may  be considered for patients in whom other radiological
maging is inconclusive (Hacker et al., 2012; Coulter and Gleeson,
003; Fonseca-Moutinho, 2005). If there is locally advanced recur-
ent VSCC, a cystoscopy and/or proctoscopy should be considered
Guideline vulvar cancer, national cancer institute, 2015; Guideline
ulvar cancer, oncoline, 2011).
. Local recurrence
Surgery is the cornerstone of treatment for local recurrent VSCC
Berek and Hacker, 2014; Salom and Penalver, 2002; Coulter and
leeson, 2003; Fonseca-Moutinho, 2005). Surgical treatment of
ocal recurrences becomes more difﬁcult with increasing tumor
ize, especially when the tumor is close to the anus or urethra.
urthermore, prior surgery with changed anatomy and, in partic-
lar, earlier radiotherapy can inﬂuence skin healing and the risk
f wound dehiscence or infection. Reconstructive surgery can be
n indispensable component of surgical treatment, for example by
sing local (fasciocutaneous) skin ﬂaps (Weikel et al., 2005) or V-
 reconstruction skin ﬂaps from the upper posterior thighs (Lee
t al., 2006; Saito et al., 2014; Rinaldi et al., 2005) or split-skin
rafts (Thomas et al., 1996). Surgery may  be contraindicated based
n comorbidity and/or extensive previous surgery (Gadducci et al.,
006; Salom and Penalver, 2002; Coulter and Gleeson, 2003). In
hese cases, radiotherapy with or without concurrent chemother-
py may  be considered, if not administered previously, preferably
ith the option of surgery for residual disease after downsizing
Berek and Hacker, 2014; Raffetto et al., 2003). Radiotherapy can besevere toxicity.
D: Stable disease; PD: Progressive disease; NS: not speciﬁed.
considered as an adjuvant or primary treatment (Faul et al., 1998).
Chemotherapy is only indicated in combination with radiotherapy
or as palliative treatment (Raffetto et al., 2003; Whitaker et al.,
1990; Russell et al., 1992). A full IFL is considered standard treat-
ment for the groins in cases of local recurrence inﬁltrating >1 mm,
where primary treatment of VSCC did not comprise full IFL (Salom
and Penalver, 2002; Coulter and Gleeson, 2003; Hopkins et al.,
1990). A recent article on the safety of SLN biopsy in local recurrent
VSCC showed that a repeat SLN biopsy is technically challenging,
but feasible. The safety of the procedure should and will be fur-
ther investigated before it is implemented in the treatment of local
recurrent VSCC (Doorn et al., 2016). We  found 12 retrospective
studies on the treatment of local recurrent VSCC. Table 4 provides
an overview of these studies, with characteristics, reported number
of re-recurrences, and 5-year overall survival (Hopkins et al., 1990;
Weikel et al., 2006; Piura et al., 1993; Faul et al., 1998; Schmidt et al.,
1992; Simonsen, 1984; Chakalova and Karagiozov, 1993; Raffetto
et al., 2003; Frischbier and Wenn, 1985; Kohler et al., 1997; Strauss
and Lampe, 1994; Buchler et al., 1979).
4.1. Surgery
Patients who have an isolated local recurrence are good can-
didates for surgical treatment, unless there is a threat for the
necessity of a colostomy. Eleven of the 12 studies on the treat-
ment of local recurrent VSCC evaluated surgery alone as treatment
for local recurrent VSCC. All 11 studies had a retrospective design.
The largest study, published in 2006 by Weikel et al., included 201
patients (Weikel et al., 2006). The other studies evaluated 13–81
patients. Surgery consisted of wide local excision, hemivulvectomy,
or radical vulvectomy, with or without groin surgery. The type of
surgery was based on the location and extent of the recurrence.
The percentage of patients who developed a second recurrence was
28–50% (Hopkins et al., 1990; Weikel et al., 2006; Faul et al., 1998;
Schmidt et al., 1992; Kohler et al., 1997; Strauss and Lampe, 1994;
Buchler et al., 1979), and 5-year survival was  20–79% (Hopkins
et al., 1990; Weikel et al., 2006; Piura et al., 1993; Faul et al., 1998;
Schmidt et al., 1992; Chakalova and Karagiozov, 1993; Frischbier
and Wenn, 1985; Kohler et al., 1997; Strauss and Lampe, 1994).
The most often encountered complications were wound infection
(40%), vaginal stricture, and urinary incontinence (Simonsen, 1984;
Buchler et al., 1979).
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In seven studies, 5–21 patients with local recurrent VSCC
ere treated with surgery and adjuvant radiotherapy (Hopkins
t al., 1990; Piura et al., 1993; Faul et al., 1998; Schmidt et al.,
992; Simonsen, 1984; Chakalova and Karagiozov, 1993; Strauss
nd Lampe, 1994). The indications for adjuvant radiotherapy are
nclear. In these studies, the percentage of subsequent recurrences
as 35–50%, with a 5-year survival of 35–79%. Most reported com-
lications after radiotherapy were skin reactions, such as moist
esquamation and skin ulceration. In some cases, interruption of
adiation treatment was  necessary (Raffetto et al., 2003).
Pelvic exenteration may  be a curative treatment option when
atients have extensive locally recurrent VSCC that is otherwise
ntreatable. Four studies have reported on pelvic exenteration as
 treatment option in cases of local recurrent VSCC. Pelvic exen-
eration achieved good symptom control, with a reported mean
verall survival of 11 months and 2-year overall survival of 57%. This
xtensive surgical procedure is associated with considerable mor-
idity, and most patients develop psychological problems due to
ajor alterations in body image and loss of sexual function. Patient
election and extensive counselling is of utmost importance before
elvic exenteration is performed (Miller et al., 1995; Kaur et al.,
012; Pathiraja et al., 2014; Tan et al., 2013).
.2. (Chemo)radiotherapy
When surgery is not possible or may  lead to high morbidity,
chemo)radiotherapy can be considered as a primary treatment
or locally recurrent VSCC, but only if patients have not previ-
usly undergone radiotherapy. Therapy plans are individualized
epending on the extent of disease and prior therapy, but they
ost often involve external beam radiotherapy (EBRT), in some
ases with a brachytherapy boost. Seven retrospective studies
ere performed that included 5–20 patients treated with primary
chemo)radiotherapy for locally recurrent VSCC (Piura et al., 1993;
aul et al., 1998; Schmidt et al., 1992; Raffetto et al., 2003; Kohler
t al., 1997; Strauss and Lampe, 1994; Buchler et al., 1979). In
eneral, treatment with primary (chemo)radiotherapy yields less
avorable treatment results than surgery with respect to 5-year
urvival (20–60% versus 20–79%, respectively) (Piura et al., 1993;
uchler et al., 1979). It should, however, be emphasised that there
s a high risk of bias with regard to therapy selection and associated
utcomes. Although most studies do not report on the selection of
herapy, it is plausible that patients with worse clinical or tumor
haracteristics were selected more often for (chemo)radiotherapy
nstead of surgical therapy. Radiotherapy-associated side effects
ere severe skin desquamation (20%) (Raffetto et al., 2003), radi-
tion ﬁbrosis (10%) (Raffetto et al., 2003), lymphedema (10%)
Raffetto et al., 2003), and, more rarely, radiation proctitis (3%).
he additional value of concurrent chemoradiotherapy in recurrent
SCC is not well documented. However, this treatment strategy
as been suggested to improve salvage of bulky locally advanced
isease, with complete response rates as high as 64% (Raffetto
t al., 2003; Blake, 2003; Beriwal et al., 2013; Moore et al., 2012).
ne study evaluated the efﬁcacy and toxicity of chemotherapy
lone (cisplatin and vinorelbine); it included nine patients with
ocal recurrent VSCC and seven patients with a groin recurrence.
 complete response was recorded in 27% of the patients and a
artial response in 13%. Stable disease was observed in 27% of the
atients and progressive disease in 33%. The median progression-
ree survival was 10 months (range 3–17 months), and overall
urvival was 19 months (1–30 months). Toxicity of the treatment
as high, especially hematological toxicity; 31% of the patients
xperienced WHO  grade 3/4 leukopenia, 69% had neutropenia,
nd 24% had anemia. Other WHO  grade 3/4 toxicities included
ausea/vomiting in 62% of the patients, neurotoxicity in 38%, and
lopecia in 62% (Cormio et al., 2009). Chemotherapy as treatmentlogy/Hematology 106 (2016) 1–13 9
for locally recurrent VSCC should only be considered as a last
resort in a palliative treatment setting, with a small chance of
response.
5. Groin recurrence
Nearly all VSCC patients with a groin recurrence die of disease,
and management is challenging (Berek and Hacker, 2014; Gonzalez
et al., 2005; Coulter and Gleeson, 2003; Stehman et al., 1996;
Woolderink et al., 2006; Woelber et al., 2009; Deka et al., 2014;
Woelber et al., 2012; Lataifeh et al., 2004). However, a recently pub-
lished study on groin recurrences found a 50% survival rate after 7
years and the authors suggest that a groin recurrence should there-
fore no longer be considered a palliative situation (Frey et al., 2016).
Choice of treatment is individualized and determined by the size
of the tumor, previous treatment, and time interval to recurrence
(Coulter and Gleeson, 2003; Stehman et al., 1996; Deka et al., 2014;
Lataifeh et al., 2004). We  found a total of 7 studies that reported
on the treatment of groin recurrences in VSCC patients. All stud-
ies had a retrospective design (Cormio et al., 2010; Hopkins et al.,
1990; Tilmans et al., 1992; Simonsen, 1984; Wagenaar et al., 2001;
Witteveen et al., 2009; Frey et al., 2016). Patients included in the
studies had local and groin recurrences, isolated groin recurrences
or groin and pelvic recurrence. An overview of the studies and their
results is provided in Table 5. Median survival was  3–19 months,
with overall survival rates of 0–50%.
Surgery, followed by radiotherapy when possible, is currently
the treatment of choice if the patient is in good general health.
Primary radiotherapy for a groin recurrence can be considered as
alternative treatment, but almost never leads to a cure (Cormio
et al., 2010; Tewari et al., 1999; Perrone et al., 2013). Five studies
report on surgery, either alone or in combination with radio-
therapy, as a treatment for groin recurrences. Surgical treatment
consisted of full IFL or debulking of the groin recurrence(s). Radio-
therapy consisted of external beam therapy. Some patients in
these studies received primary radiotherapy. In general, the rec-
ommended dose for radiotherapy is 46–50 Gy in fractions of
1.8–2.0 Gy, with a boost to 56–60 Gy to the site of the involved
lymph node(s), especially in cases of extracapsular extension, and
to 64–66 Gy to macroscopic residual disease. One study combined
surgery with chemo- and radiotherapy in 10 of the 30 included
patients. Which chemotherapy was  not speciﬁed by the authors
(Frey et al., 2016). Progression-free survival and overall survival
was low, with median survival rates varying from 6 to 16 months.
Only a few patients survived for >5 years without evidence of dis-
ease after treatment (Cormio et al., 2010; Hopkins et al., 1990;
Tilmans et al., 1992; Simonsen, 1984). However, in the most
recently published study a ﬁve-year survival of 50% was  found.
Especially patients who underwent combined therapy, surgery
with (chemo)radiotherapy had a better overall survival after groin
recurrence in comparison to patients with single-mode therapy (HR
0.25, p = 0.037) (Frey et al., 2016). Earlier studies already suggested
better outcomes for concurrent chemoradiotherapy, also based on
efﬁcacy of the treatment for advanced primary disease (Beriwal
et al., 2013; Gill et al., 2015). Concurrent chemoradiotherapy is rec-
ommended for treatment of (bulky) groin recurrence, followed by
resection of the residual tumor if feasible (Gill et al., 2015; Reade
et al., 2014; Montana et al., 2000). Chemotherapy as a stand-alone
treatment for groin recurrence is only considered in a palliative set-
ting, when surgery or radiotherapy are not advisable (Wagenaar
et al., 2001; Witteveen et al., 2009). Two studies evaluated pal-
liative treatment of a groin recurrence with chemotherapy alone.
These studies found a median progression-free survival of 2.6–4
months, with a median overall survival of 7–9 months (Wagenaar
et al., 2001; Witteveen et al., 2009). In other words, palliative
1  Onco
c
w
5
l
r
w
s
l
S
a
d
H
1
i
i
e
r
u
w
p
p
f
w
p
f
w
r
g
a
e
r
s
6
T
a
I
c
p
a
o
c
a
a
W
m
a
i
w
2
(
O
a
1
m
l
p
I
E0 L.S. Nooij et al. / Critical Reviews in
hemotherapy for groin recurrences yields short response rates
ith substantial side effects.
.1. Skin bridge recurrence
Skin bridge recurrence can be considered a special type of
ocoregional recurrence, with a clinical course comparable to groin
ecurrence and an extremely poor prognosis, despite treatment
ith surgery and/or radiotherapy. It has been hypothesized that
kin bridge recurrences evolve from metastatic tumor emboli in
ymphatic vessels arrested in their migration (Rouzier et al., 2002).
kin bridge recurrences in vulvar cancer are uncommon, but they
re relevant because of the poor outcome. The incidence has been
escribed as 0–9% (Rouzier et al., 2002; Hopkins et al., 1990; de
ullu et al., 2002; Piura et al., 1993; Woolderink et al., 2006; Rose,
999). Since the introduction of a surgical approach with separate
ncisions (instead of “en-bloc” surgery), there has been an increased
ncidence of skin bridge recurrences (de Hullu et al., 2002). De Hullu
t al. investigated the prevalence of groin and skin bridge recur-
ences in 253 VSCC patients primarily treated with surgery. Group I
nderwent radical vulvectomy with en bloc IFL, and group II under-
ent wide local excision with IFL through separate incisions. The
revalence of skin bridge recurrences was 6.3% in group II com-
ared to 1.3% in group I (p = 0.029) (de Hullu et al., 2002). Rose et al.
ound ﬁve skin bridge recurrences in a group of 126 patients (3.9%)
ith VSCC (Rose, 1999). Rouzier et al. investigated relapses and
rognostic factors associated with skin bridge recurrences. They
ound that margin status (p = 0.001) and tumor size >2 cm (p < 0.05)
ere signiﬁcantly associated with the occurrence of skin bridge
ecurrences. Seven patients had a skin bridge recurrence out of a
roup of 215 VSCC patients. None of the seven patients were alive
fter 1 year (Rouzier et al., 2002). On the other hand, Woolderink
t al. reported on 125 patients with VSCC; none had a skin bridge
ecurrence (Woolderink et al., 2006). In conclusion, literature on
kin bridge recurrences is limited and prognosis is still very poor.
. Distant recurrence
Patients with distant recurrence have a very poor prognosis.
here is no standard therapy for these patients, and treatment is
lways palliative (Tilmans et al., 1992; Fonseca-Moutinho, 2005).
n cases of isolated recurrence in the pelvis, radiotherapy or
oncurrent chemoradiotherapy can be considered. Patients with
ara-aortic nodal recurrences can be treated with radiation ther-
py to relieve symptoms. Radiation can also be used for palliation
f pain due to bone metastasis. Some studies have evaluated
hemotherapy for patients with metastatic vulvar cancer, often as
 last resort if patients are not amenable to surgery or radiother-
py. These studies are summarized in Table 6 (Tilmans et al., 1992;
itteveen et al., 2009; Raffetto et al., 2003; Durrant et al., 1990). The
ost commonly used agents are paclitaxel, bleomycin, cisplatin
nd 5-ﬂuorouracil, but large series are lacking. Although some reg-
mens were associated with limited clinical activity, response rates
ere low, with complete response rates of 7–20% (Witteveen et al.,
009; Raffetto et al., 2003) and partial response rates of 7–80%
Witteveen et al., 2009; Raffetto et al., 2003; Durrant et al., 1990).
ther patients had stable or progressive disease during chemother-
py (Tilmans et al., 1992; Witteveen et al., 2009; Durrant et al.,
990). Response was usually short, with a median survival of 4–7
onths. Response rates of recurrences in irradiated areas are even
ower.
Recently, EGFR targeting therapy has been suggested as a thera-
eutic option in the treatment of patients with distant recurrences.
n a phase II trial on the effect of erlotinib (an inhibitor of the
GFR tyrosine kinase) 32 patients with distant recurrences werelogy/Hematology 106 (2016) 1–13
included. Eight patients were treated with one cycle of 28 days
oral erlotinib followed by surgery or chemoradiation (cohort 1)
and 24 patients were treated with multiple cycles of oral erlotinib
(cohort 2, mean 3.3 cycles). In cohort 1 35% of the patients showed
a partial response to erlotinib therapy and in cohort 2 22% of the
patients. Progressive disease was seen in 6% and 23% of the patients,
respectively. Other patients had stable disease or were unevaluable,
because they failed to complete a minimum number of cycles of
therapy due to serious adverse events. Adverse events included an
allergic reaction, diarrhoea, dehydration, electrolyte abnormalities,
gastro-intestinal bleed and ischemic colitis (all grade 3 toxicity).
Two patients experienced grade 4 acute renal failure (Horowitz
et al., 2012). These results are promising and new studies regard-
ing targeted therapies in VSCC patients with distant recurrences
are expected in the next future.
7. Summary and recommendations
In cases of local recurrence, surgical resection is the treatment
of choice. If needed, combined with reconstructive and/or groin
surgery. If primary surgery is not an option because of tumor
growth adjacent to the urethra or anus, (chemo)radiotherapy can
be a good alternative, either as deﬁnitive treatment or prior to
surgery for downsizing the tumor. Chemotherapy alone is con-
sidered palliative treatment and is not recommended due to the
low response rates and short duration of response. The pre-
ferred treatment for groin and skin bridge recurrence is surgery,
followed by radiation therapy if not previously irradiated. Concur-
rent chemoradiotherapy can be considered if primary resection
does not seem feasible, either preoperatively for downsizing of
a bulky groin recurrence or as deﬁnitive or palliative treatment.
Distant recurrences of VSCC are rare, and treatment is only pal-
liative. Chemotherapy can be considered, but it has low response
rates. Future studies regarding targeted treatment in patients with
metastatic VSCC are expected. Management of recurrent VSCC
should be individualized and requires an experienced, multidis-
ciplinary team approach in an oncological center.
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